Skip to search formSkip to main contentSkip to account menu

CR 2945

Known as: CR-2945, CR2945 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Most patients with peptic ulcer disease are currently treated with proton pump inhibitors or histamine H2 receptor antagonists… 
2008
2008
Background and Aim:  Cholecystokinin (CCK) and gastrin exert their influences via CCK receptors. This research was conducted to… 
2007
2007
Cholecystokinin (CCK) is one of the most abundant neuropeptides in the central nervous system (CNS) where it promotes important… 
2006
2006
In urethane‐anaesthetised female Wistar rats, intravenous injection of the panicogenic CCKB receptor agonist pentagastrin (0.002… 
2004
2004
AIM To investigate the effect of lipopolysaccharide (LPS) on the expression and the binding characteristics of cholecystokinin… 
2002
2002
Background/Aims: The potential role of gastrin and the cholecystokinin-B (CCK-B)/gastrin receptor in the genesis of colon cancer… 
2001
2001
Our previous experimental data demonstrated that a new gastrin receptor antagonist (CR2945) has a chemopreventive effect on… 
1999
1999
This study tested the effect of a new gastrin receptor antagonist, CR2945, on colorectal cancer induced by 1,2-dimethylhydrazine… 
1998
1998
The effects of CR 2945, an antranilic acid derivative member of a novel family of non-peptide CCKB receptor antagonists, have…